China Pharmaceutical University and Shanghai Institute of Materia Medica of the Chinese Academy of Sciences have patented benzimidazole compounds acting as ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) inhibitors reported to be useful for the treatment of cancer, infections, autoimmune disease and inflammatory disorders.
Researchers from Interius Biotherapeutics Inc. presented the development and preclinical evaluation of a novel gene therapy candidate, INT-2104, as potential candidate for the treatment of B-cell malignancies.
“From such a stick, such a splinter,” is a popular Spanish saying to explain how a son resembles his father. Like father, like son. The first Spotlight on Immuno-Oncology conference of the American Society of Gene & Cell Therapy (ASGCT) is the splinter of the ASGCT annual meeting, which brought together a group of experts in this field. It took place on Aug. 1 and 2, 2023, starting with a series of talks on “B Cell Malignancies and Beyond.”
Precision medicine startup Solu Therapeutics has raised $31 million in an oversubscribed seed round to advance a therapeutic candidate based on technology that identifies cell surface, tumor-associated targets that antibodies alone fail to latch onto. The company was founded by venture capital firm Longwood Fund and has high hopes for its cytotoxicity targeting chimera platform. “[It] has the potential to unlock new tumor-associated antigens and develop molecules that deplete pathogenic immune cells and extend the half-life of small-molecule antagonists and agonists,” CEO and co-founder of Solu, David Donabedian, told BioWorld.
Research at Genfleet Therapeutics Inc. has led to the development of mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer.
Mitogen-activated protein kinase kinase (MAP2K; MEK; MAPKK) inhibitors have been reported in an Immuneering Corp. patent as potentially useful for the treatment of cancer.
Recludix Pharma Inc. has disclosed signal transducer and activator of transcription 3 (STAT3) and/or STAT6 inhibitors reported to be useful for the treatment of cancer and inflammatory disorders.
The FDA has cleared Qualigen Therapeutics Inc.’s IND application for QN-302, a potential best-in-class small molecule G-Quadruplex (G4)-selective transcription inhibitor.
RSS
